Target Name: LOC105376177
NCBI ID: G105376177
Review Report on LOC105376177 Target / Biomarker Content of Review Report on LOC105376177 Target / Biomarker
LOC105376177
Other Name(s): LOC105376177 variant X1 | uncharacterized LOC105376177 | Uncharacterized LOC105376177, transcript variant X1

LOC105376177: A Potential Drug Target for Chronic Stress?

LOC105376177 (LOC105376177 variant X1) is a protein that is expressed in various tissues of the human body, including the brain, heart, and blood vessels. It is a member of the heat shock protein (HSP) family, which are proteins that are expressed in response to increased levels of thermal stress in the body.

HSPs are known for their ability to interact with a variety of molecules, including drugs and toxins. This makes them an attractive target for drug development, as drugs that can interact with HSPs have the potential to treat a wide range of diseases.

LOC105376177 variant X1 is a specific variant of the HSP protein that has been shown to interact with a variety of drugs, including chemotherapy drugs and anti-inflammatory drugs. This suggests that LOC105376177 variant X1 may be a drug target (or biomarker) for the treatment of various diseases.

One of the main ways that LOC105376177 variant X1 interacts with drugs is through its role in the detoxification of drugs. Many drugs are metabolized by the liver, and the rate at which they are metabolized can be affected by various factors, including the presence of other proteins in the body. LOC105376177 variant X1 has been shown to help regulate the metabolism of drugs by the liver, which may have implications for the effectiveness of drugs that are used to treat various diseases.

Another way that LOC105376177 variant X1 interacts with drugs is through its role in the transport of drugs across cell membranes. Many drugs have to be transported across the cell membrane in order to be effective, and LOC105376177 variant X1 has been shown to be involved in this process. This may have implications for the transportation of drugs across the cell membrane in diseases where the drug transport is defective.

LOC105376177 variant X1 may also be a drug target (or biomarker) due to its role in the regulation of cellular stress responses. Many diseases are caused by chronic stress, and the body's stress response is a critical factor in maintaining overall health. LOC105376177 variant X1 has been shown to be involved in the regulation of cellular stress responses, which may have implications for the treatment of diseases caused by chronic stress.

In addition to its potential role as a drug target (or biomarker), LOC105376177 variant X1 is also of interest as a potential therapeutic agent. The use of small molecules, such as drugs, to treat diseases is a common practice in modern medicine. LOC105376177 variant X1 may be a small molecule that can be used to treat various diseases, including those caused by chronic stress.

In conclusion, LOC105376177 variant X1 is a protein that is expressed in various tissues of the human body and has been shown to interact with a variety of drugs. This suggests that LOC105376177 variant X1 may be a drug target (or biomarker) for the treatment of various diseases. Further research is needed to fully understand the role of LOC105376177 variant X1 in the treatment of diseases.

Protein Name: Uncharacterized LOC105376177

The "LOC105376177 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105376177 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC105376187 | LOC105376193 | LOC105376196 | LOC105376205 | LOC105376206 | LOC105376208 | LOC105376211 | LOC105376214 | LOC105376219 | LOC105376223 | LOC105376225 | LOC105376234 | LOC105376244 | LOC105376247 | LOC105376250 | LOC105376253 | LOC105376270 | LOC105376287 | LOC105376326 | LOC105376344 | LOC105376356 | LOC105376360 | LOC105376361 | LOC105376372 | LOC105376375 | LOC105376387 | LOC105376391 | LOC105376397 | LOC105376400 | LOC105376407 | LOC105376412 | LOC105376413 | LOC105376422 | LOC105376435 | LOC105376440 | LOC105376442 | LOC105376481 | LOC105376482 | LOC105376483 | LOC105376486 | LOC105376502 | LOC105376504 | LOC105376505 | LOC105376512 | LOC105376523 | LOC105376536 | LOC105376548 | LOC105376558 | LOC105376559 | LOC105376566 | LOC105376576 | LOC105376579 | LOC105376583 | LOC105376595 | LOC105376611 | LOC105376622 | LOC105376626 | LOC105376627 | LOC105376645 | LOC105376659 | LOC105376707 | LOC105376732 | LOC105376740 | LOC105376755 | LOC105376767 | LOC105376781 | LOC105376786 | LOC105376805 | LOC105376809 | LOC105376815 | LOC105376817 | LOC105376818 | LOC105376819 | LOC105376823 | LOC105376845 | LOC105376850 | LOC105376885 | LOC105376898 | LOC105376934 | LOC105376981 | LOC105376991 | LOC105377013 | LOC105377016 | LOC105377022 | LOC105377043 | LOC105377046 | LOC105377054 | LOC105377056 | LOC105377095 | LOC105377097 | LOC105377102 | LOC105377103 | LOC105377134 | LOC105377135 | LOC105377136 | LOC105377139 | LOC105377142 | LOC105377149 | LOC105377155 | LOC105377156